Gilead’s HIV franchise generated $19.612B in 2024, but faces future funding challenges. Learn why GILD stock is a "Hold" amid ...

"We tried not to make the same show — it's got younger voices, it's got a completely different feel and a completely ...

She hasn’t just starred as the rebel June Osborne since the beginning of the series. Moss has directed several episodes of ...

The Town pays $400,000 to send 18 Gilead children to school, said Town Clerk Patsy Cox, who added that they would not have a ...

The final season of "The Handmaid's Tale," premiering April 8 on Hulu, expands the themes and story of Margaret Atwood's ...

As the sixth and final season lands on Hulu, THR’s chief TV critic reflects on how the dystopian series was shaped by the ...

Elisabeth Moss and Yvonne Strahovski still shine in the final chapters of the dystopian thriller "The Handmaid's Tale" ...

This final season may be more of a cliffhanger than a conclusion. (A sequel is in the works.) The question it asks is: how ...

The Handmaid's Tale' creator Bruce Miller revealed if there is a chance Alexis Bledel will reprise the role of Emily in the ...

Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...

No matter the outcome, The Handmaid’s Tale is a masterclass in acting, directing, and writing—and the final season proves this even further.

On CNBC's “ Halftime Report Final Trades ,” Rob Sechan of NewEdge Wealth said Gilead Sciences, Inc. GILD +0.78% Get Free Report is one of the best-performing names in one of the best-performing ...